The physiologically-based whole-body model of the glucose-insulin-glucagon regulatory system

Whole-body PBPK model of Vancomycin

Whole-body PBPK model of midazolam as CYP3A4 DDI victim drug

Whole-body PBPK model of itraconazole as CYP3A4 and P-gp DDI perpetrator drug

Whole-body PBPK model of efavirenz as CYP3A4 perpetrator drug

Whole-body PBPK model of cimetidine (OCT2/MATE and CYP3A4 DDI perpetrator drug)

Whole-body PBPK model of dapagliflozin

Whole-body PBPK model of Amikacin

Whole-body PBPK model of ethinylestradiol as CYP1A2 DDI perpetrator drug

Whole-body PBPK model of moclobemide as a substrate and a moderate inhibitor of CYP2C19

Whole-body PBPK model of omeprazole as a substrate of CYP2C19 and CYP3A4 and an inhibitor of CYP2C19.

Whole-body PBPK model of Raltegravir

Whole-body PBPK model of tizanidine as a substrate of CYP1A2

Whole-body PBPK model of atazanavir

Whole-body PBPK model of alprazolam

Whole-body PBPK model of alfentanil as CYP3A4 DDI victim drug

Whole-body PBPK model of montelukast